The FDA regulates both the medications used for weight loss and the blood donation process through regulations including 21 CFR 630.10 and 630.15, but there is no specific FDA prohibition against donating blood while taking GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists
People starting on a GLP-1 medication must be counseled that they are likely going to have to take some form of a GLP-1 drug for the rest of their life, or at least for many years, depending on developments in pharmaceuticals, Oshman says
Incretin-based therapies: viewpoints on the way to consensus
than other wealthy nations
Lower back pain is not listed as a common or characteristic adverse effect in the FDA-approved prescribing information for semaglutide formulations (Ozempic, Wegovy, or Rybelsus)
Studies show that users experience hair loss through indirect pathways rather than direct medication effects [11]